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Abstract Since its clinical introduction in 1998, the
topoisomerase I inhibitor irinotecan has been widely used
in the treatment of solid tumors, including colorectal,
pancreatic, and lung cancer. Irinotecan therapy is charac-
terized by several dose-limiting toxicities and large
interindividual pharmacokinetic variability. Irinotecan has
a highly complex metabolism, including hydrolyzation by
carboxylesterases to its active metabolite SN-38, which is
100- to 1000-fold more active compared with irinotecan
itself. Several phase I and II enzymes, including cyto-
chrome P450 (CYP) 3A4 and uridine diphosphate glu-
curonosyltransferase (UGT) 1A, are involved in the
formation of inactive metabolites, making its metabolism
prone to environmental and genetic influences. Genetic
variants in the DNA of these enzymes and transporters
could predict a part of the drug-related toxicity and efficacy
of treatment, which has been shown in retrospective and
prospective trials and meta-analyses. Patient characteris-
tics, lifestyle and comedication also influence irinotecan
pharmacokinetics. Other factors, including dietary restric-
tion, are currently being studied. Meanwhile, a more tai-
lored approach to prevent excessive toxicity and optimize
efficacy is warranted. This review provides an updated
overview on today’s literature on irinotecan pharmacoki-
netics, pharmacodynamics, and pharmacogenetics.
Key Points
Irinotecan metabolism is complex due to the
involvement of many enzymes and transporters, and
is therefore prone to drug–drug interactions. Prior to
starting with irinotecan chemotherapy, patients
should be evaluated for possible interactions with
comedication.
Single nucleotide polymorphisms in several drug
metabolizing enzymes (e.g. uridine diphosphate
glucuronosyltransferase [UGT] 1A1, UGT1A7,
UGT1A9) and drug transporters (e.g. ATP-binding
cassette [ABC] B1, ABCC1) have been reported to
be significantly associated with irinotecan toxicity.
Caucasian patients should be screened for
UGT1A1*28 and Asian patients for UGT1A1*6 in
advance of irinotecan treatment as these
polymorphisms are common in those populations
and dosing can be personalized if UGT1A1
functioning is constitutionally altered.
Despite existing genotype-based dosing guidelines,
upfront UGT1A1 genotyping is not yet routinely
performed in patients starting with irinotecan
chemotherapy.
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1 Introduction
Irinotecan (CPT-11) is a camptothecin derivative that
demonstrates anticancer activity in many solid tumors.
Currently, it is widely used in the treatment of colorectal,
pancreatic, and lung cancer. Irinotecan is the prodrug for
SN-38, which inhibits topoisomerase-I, an enzyme
involved in DNA replication [1, 2]. SN-38 is 100- to
1000-fold more cytotoxic than irinotecan, and its exposure
is highly variable [3]. SN-38 is inactivated by further
enzymatic conversion into SN-38 glucuronide (SN-38G).
2 Pharmacokinetics
2.1 Distribution
Irinotecan is a hydrophilic compound with a large volume
of distribution estimated at almost 400 L/m2 at steady state
[4]. At physiological pH, the lactone-ring of irinotecan and
SN-38 can be hydrolyzed to a carboxylate isoform (Fig. 1).
Consequently, a pH-dependent equilibrium between these
forms exists [5]. As only the lactone form has antitumor
activity, a small change in pH could alter the pharma-
cokinetics and efficacy of irinotecan [6]. However in
plasma the carboxylate form of irinotecan and the lactone
form of SN-38 dominate [7, 8]. This could be explained by
a higher tissue distribution of irinotecan lactone and the
preferential binding of SN-38 lactone to plasma proteins
[4, 9]. Conversion of irinotecan lactone to carboxylate
within the circulation is rapid, with an initial half-life of
between 9 and 14 min, which results in a 50% reduction in
irinotecan lactone concentration after 2.5 h, compared with
end of infusion (66 vs. 35%) [4, 7, 8].
After the end of drug infusion, a rapid decrease in
irinotecan plasma concentrations is seen. Peak concentra-
tions of SN-38 are reached within 2 h after infusion [8].
Irinotecan is assumed to exhibit linear pharmacokinetics
because of the correlation between dose and systemic
exposure, which is highly variable between patients [8]. In
plasma, the majority of irinotecan and SN-38 is bound to
albumin, which has a stronger binding capacity for the
more hydrophobic active metabolite, and albumin also
stabilizes the lactone forms of irinotecan and SN-38 [10].
In blood, SN-38 is almost completely bound, with two-
thirds located in platelets and, predominantly, red blood
cells [11]. The binding constant of SN-38 with erythrocytes
is almost 15-fold higher than that of irinotecan [11].
Thus far, several population pharmacokinetic models of
irinotecan have been developed. All models confirmed the
large interindividual variability in pharmacokinetic
parameters of approximately 30%. In general, a three-
compartmental model for irinotecan and a two-compart-
mental model for SN-38 is assumed [4, 12–16]. A mean
SN-38 distribution half-life was estimated to be very short
(approximately 8 min) [13]. Several models showed a
second peak in the SN-38 plasma area under the curve
(AUC), which was explained by an enterohepatic re-
Fig. 1 pH-dependent equilibrium of irinotecan and SN-38 isoforms
F. M. de Man et al.
circulation of SN-38. SN-38 is reabsorbed after intestinal
deconjugation of SN-38G by (bacterial) b-glucuronidases
[15]. Alternatively, release of SN-38 from erythrocytes has
also been proposed to cause this second plasma peak [17].
2.2 Metabolism
2.2.1 Metabolism by Carboxylesterases
and Butyrylcholinesterase
The prodrug irinotecan is hydrolyzed into the active
metabolite SN-38 by two isoforms of carboxylesterases
(CES1 and 2) and butyrylcholinesterase in the human body
(Fig. 2) [18, 19]. CES1 and CES2 are localized in liver,
colon, kidney, and blood cells, while butyrylcholinesterase
is mainly found in plasma [20]. Conversion by these
esterases mainly occurs intrahepatically and is a relatively
slow and inefficient process as only 2–5% of irinotecan is
converted into SN-38 [12, 18]. CES2 has a 12.5-fold higher
affinity for irinotecan than CES1 and is therefore the pre-
dominant enzyme in this conversion [21–23]. In addition,
this process also occurs in blood, where butyryl-
cholinesterase has a sixfold higher activity than CES [20].
After conversion, SN-38 is actively transported into the
liver by the organic anion transporting polypeptide (OATP)
1B1 transporter (Fig. 2) [24].
Many studies have investigated intratumoral CES
activity, by which irinotecan can be activated at the site of
action. Indeed, the amount of CES activity could be related
to irinotecan efficacy, although preclinical work showed
conflicting results [25–30]. Many preclinical studies have
been performed to selectively increase the intratumoral
CES activity with a virus or engineered stem cells, thereby
aiming to increase irinotecan efficacy [31–38]. Although a
few studies could indeed reverse irinotecan resistance
in vitro and in mice, this mechanism has not yet been
investigated in a clinical setting.
To our knowledge, no clinically relevant drug–drug
interactions (DDIs) involving CES have been reported for
irinotecan, although both inhibitors and inducers of CES
have been described, which could potentially influence the
rate of irinotecan conversion to SN-38 [39].
2.2.2 Metabolism by Uridine Diphosphate
Glucuronosyltransferases
SN-38 is inactivated via glucuronidation to SN-38G by
uridine diphosphate glucuronosyltransferase (UGT) and
excreted into the bile [40, 41]. Several UGT subtypes are
involved in the hepatic (UGT1A1, UGT1A9) and extra-
hepatic (UGT1A1, UGT1A7, UGT1A10) conversion of
SN-38, of which UGT1A1, UGT1A7 and UGT1A9 are the
major isoenzymes [42–46]. SN-38G is formed almost
directly after SN-38 formation, explaining the short half-
life of SN-38 [47]. Plasma concentrations of SN-38G are
the highest among all irinotecan metabolites, suggesting a
Fig. 2 Irinotecan metabolism and excretion. The main excretion
routes of all metabolites are depicted. * Active metabolite. CES
carboxylesterase, BES butyrylcholinesterase, CYP cytochrome P450
enzymes, UGT uridine diphosphate glucuronosyltransferase, b-gluc
b-glucuronidase
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highly efficient glucuronidation rate of SN-38 into SN-38G
[4]. UGT1A1 also conjugates bilirubin, and a significant
correlation between SN-38 and bilirubin glucuronidation
has been observed [42]. In addition, patients genetically
predisposed with decreased UGT1 activity, e.g. in Gilbert’s
syndrome, are at higher risk for severe toxicity when
treated with irinotecan [48]. In addition, many other UGT
polymorphisms have been described and their influence on
irinotecan pharmacokinetics and pharmacodynamics is
summarized in Sect. 4.
2.2.3 Metabolism by Cytochrome P450 Enzymes
Irinotecan is also metabolized by intrahepatic cytochrome
P450 (CYP) enzymes, i.e. CYP3A4 and CYP3A5, into
inactive metabolites—APC and NPC [49]. In contrast to
APC, NPC can be converted to SN-38 by CES1 and CES2
in the liver, but to a lesser amount than irinotecan [50]. The
importance of CYP3A4 and CYP3A5 in irinotecan meta-
bolism is underlined by the strong correlation between
irinotecan and midazolam clearance [51]. Midazolam is an
important CYP3A probe drug, and we previously con-
ducted a randomized clinical trial aiming to individualize
irinotecan dosing by use of a CYP3A4 phenotype-based
algorithm. By dosing on this algorithm, the interindividual
variability in irinotecan and SN-38 exposure dramatically
reduced compared with conventional dosing [52]. In
addition, smoking, some herbal supplements, and comed-
ication are known to induce or inhibit CYP3A enzymes,
resulting in interactions with irinotecan, which are sum-
marized in more detail in Sect. 2.5.
2.2.4 Metabolism by b-Glucuronidases
As previously mentioned, SN-38G can be deconjugated
into SN-38 by b-glucuronidases produced by intestinal
bacteria, which could result in an enterohepatic circulation
of SN-38 [15, 53–55]. In addition, b-glucuronidase activity
has been correlated to intestinal damage and diarrhea in
rats/mice, which could (potentially) be reduced by
inhibiting b-glucuronidase with antibiotics (penicillin and
streptomycin) or amopaxine [56, 57]. Nonetheless,
attempts to reduce b-glucuronidase activity by neomycin
did not significantly alter the irinotecan pharmacokinetic
profile in patients [58].
2.3 Elimination
The clearance of irinotecan is mainly biliary (66%) and
independent of dose, estimated at 12–21 L/h/m2 [59, 60].
Irinotecan is transported into the bile by several ATP-
binding cassette (ABC) transporters (i.e. ABCB1, ABCC2,
and ABCG2) [see Fig. 2] [61–63]. In addition, active efflux
by ABCB1 has been shown to lead to low intracerebral
irinotecan concentrations in mice [64]. All metabolites,
except SN-38G, are predominately excreted in feces,
although they are also detectable in urine [4, 59]. Terminal
elimination half-lives (t) between 5 and 18 h for irinote-
can, and between 6 and 32 h for SN-38, were reported
[4, 12–14, 59, 65–71]. However, it was later shown that the
t was initially underestimated as SN-38 concentrations
can be detected up to 500 h after infusion [72, 73].
The wide interindividual variability in irinotecan clear-
ance is still not completely understood. Primarily, a
decreased clearance in patients with altered hepatic func-
tion has been described [12, 13]. Additionally, increasing
age may negatively influence irinotecan clearance,
although this could not be confirmed in another analysis
[13, 74]. Conflicting effects of gender on irinotecan phar-
macokinetics have also been proposed. Several studies
reported higher irinotecan exposure in women, which, in
part, could be explained by decreased SN-38 (metabolic)
clearance [13, 59, 75], while others found no gender effect
[4, 74, 76]. Several factors such as dose, timing of
administration, enzyme activity, and hematocrit levels
might be responsible for these differences. In addition, firm
conclusions cannot be drawn for weight [13, 77]. Worse
clinical performance has been demonstrated to decrease
irinotecan clearance [13]. However, interindividual vari-
ability does not seem to be related to body size measures
such as body surface area (BSA). Although irinotecan dose
is generally based on BSA, it has been shown that BSA and
other body size measures do not predict irinotecan phar-
macokinetics, and that flat-fixed dosing could be a safe
alternative [74, 78].
2.4 Other Formulations and Administrations
2.4.1 Other Formulations
Furthermore, several other irinotecan formulations have
been evaluated. First, oral administration of several dif-
ferent formulations has been investigated and deemed
feasible in phase I trials [79–81], but its poor and highly
variable bioavailability have limited its current clinical
usability [82].
Second, irinotecan drug-eluting beads (DEBIRI) have
been developed to control drug release and are mostly used
as regional administration. DEBIRI administered into the
hepatic artery resulted in higher and prolonged intratu-
moral irinotecan and SN-38 exposure in liver metastases,
whereas systemic exposure was lower than after intra-
venous administration [83–85]. Hepatic arterial infusion of
DEBIRI has been demonstrated to be an effective treatment
for unresectable liver metastases [86].
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Third, liposomal irinotecan has been developed and is
clinically used. Encapsulated into liposomes, irinotecan is
stable for a longer period of time, resulting in increased
accumulation in tumor tissue and thereby increasing its
effect, as described further in Sect. 3.2 [87].
2.4.2 Other Variations in Administration
Irinotecan administration based on circadian timing
improved clinical outcome in several clinical trials
[88–90], probably due to the circadian rhythm of enzymes
and transporters involved in irinotecan pharmacokinetics
and pharmacodynamics [91–93]. However, pharmacoki-
netic consequences have only been investigated in a small
randomized study in which an increased metabolic ratio
(SN-38/irinotecan AUC) and smaller interindividual vari-
ability were found after circadian-timed dosing [94].
Trials on two different—more regional infusion meth-
ods—have been conducted. First, locoregional therapy with
irinotecan infusion into the hepatic artery has been evalu-
ated for the treatment of unresectable liver metastases;
different irinotecan formulations have been demonstrated
to be safe and effective [95, 96]. This approach resulted in
lower systemic exposure to irinotecan and an increased
conversion of irinotecan into SN-38 compared with intra-
venously administered irinotecan [97]. Second, the use of
irinotecan as hyperthermic intraperitoneal chemotherapy
(HIPEC) has been investigated as a treatment option for
colorectal peritoneal metastases [98–103]. A small fraction
of irinotecan is rapidly converted intraperitoneally into SN-
38; systemic maximum concentration (Cmax) of SN-38 has
been observed 30 min after intraperitoneal administration
[98, 100].
Although these different administration methods have
been investigated for several years, there is still insufficient
evidence that implementing these strategies in daily care
could be beneficial.
2.5 Drug–Drug Interactions (DDIs)
2.5.1 DDIs with Anticancer Drugs
Many anticancer agents have been investigated in combi-
nation with irinotecan, of which no significant pharma-
cokinetic interactions with irinotecan have been reported
for oxaliplatin, 5-fluorouracil/leucovorin, capecitabine, and
monoclonal antibodies [66, 70, 104–123]. In contrast,
paclitaxel combined with irinotecan in a 3-weekly regimen
caused a significant increase in irinotecan, SN-38, and SN-
38G exposure, which was assumed to be caused by com-
petitive inhibition of ABCB1 (Table 1) [124]. Sequencing
the administration of paclitaxel after irinotecan seems to
improve their synergistic anticancer effects [125], but
irinotecan pharmacokinetics are not significantly altered in
either sequence [125, 126]. Systemic SN-38 exposure was
found to be reduced in patients concomitantly treated with
tegafur (S-1) or carboplatin [127–129], of which the latter
also reduced irinotecan exposure. Patients seemed to tol-
erate irinotecan better when thalidomide was coadminis-
tered in two phase II studies in which SN-38G exposure
was increased at the expense of SN-38 exposure [130].
However, the pharmacokinetic differences could not be
replicated [131, 132] and might be caused by confounding
as half of the patients also used antiepileptic drugs (AEDs)
[130].
Tyrosine kinase inhibitors (TKIs) have become very
popular in cancer treatment but are also known for their
modulating effects on drug-metabolizing enzymes [133].
Several TKIs, i.e. imatinib, pazopanib, sunitinib, lapatinib
and gefitinib, have been investigated in combination with
irinotecan-containing regimens [134–141]. With the
exception of pazopanib and lapatinib, all of these combi-
nations led to excessive toxicity and have therefore not
been evaluated further for clinical use. Increased exposure
to irinotecan or SN-38 due to the inhibition of CYP3A4,
ABCB1, or ABCG2 has been suggested as a cause of the
intolerance of irinotecan combined with TKIs, but a
pharmacodynamic interaction cannot be ruled out.
2.5.2 DDIs with Non-Anticancer Drugs
Concomitant treatment with non-anticancer drugs such as
AEDs, certain antidepressants, antiretroviral drugs, and
nonsteroidal anti-inflammatory drugs (NSAIDs) have been
shown to affect irinotecan pharmacokinetics or pharma-
codynamics. The combination with the potent CYP3A4
inhibitor ketoconazole was one of the first significant DDIs
described for irinotecan (Table 1) [142]. Anecdotally,
severe rhabdomyolysis syndrome has been described in a
patient using irinotecan and citalopram [143]. Although
pharmacokinetic data were not available, competitive
metabolism by CYP3A4 was suspected as the underlying
mechanism. Hypothetically, other strong CYP3A4-in-
hibiting antidepressants such as nefazodone could be sus-
pected for an interaction with irinotecan [144].
AEDs are also known for inducing CYP3A, UGTs and
CES [145]. The influence of phenytoin, phenobarbital, and
carbamazepine on irinotecan pharmacokinetics was eval-
uated in a population pharmacokinetic model, which sug-
gested that patients using these AEDs should receive a 1.7-
fold higher irinotecan dose to reach the same exposure as in
patients without AEDs [75]. Individual patients may
require an even higher dose, as indicated by a fourfold
higher irinotecan clearance and tenfold lower systemic SN-
38 exposure in a patient receiving phenytoin [146].
Therefore, the combination of phenytoin and irinotecan
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Table 1 Drug–drug interactions with irinotecan
Drug/OTC/lifestyle N Enzyme/transporter Irinotecan dose PK alterations References
Anticancer drugs
Paclitaxel
135–200 mg/m2
D8
31 ABCB1 40–60 mg/m2
D1? 8, Q3W
Irinotecan
SN-38
SN-38G
AUC24.5 32.7% :
AUC24.5 40.4% :
AUC24.5 46.2% :
[124]
Thalidomide 400 mg od (for 14D) 16 350 mg/m2,Q3W SN-38
SN-38G
AUC48 74% ;
AUC48 28% :
[130]a
S-1 (tegafur)
100/120 mg/m2, 4–7D
4 ABCG2 100–200 mg/m2
Q2 W
SN-38: AUC24 50% ; [128]
Imatinib 300–600 mg od
Cisplatin 30 mg/m2
D1? 8
6 CYP3A4, CYP3A5
CYP2C9
65 mg/m2
D1? 8, Q3W
Irinotecan AUC8 67% :, CL
36% ;
[134]
Lapatinib 1250 mg/day
Leucovorin 200 mg/m2
5-FU 600 mg/m2
12 CYP3A4
OATP1B1
ABCB1
ABCG2
108 mg/m2
Q2W
SN-38 AUC24 41%:,
Cmax 32%:
[137]
Non-anticancer drugs
Ketoconazole 200 mg od for 2D 7 CYP3A4 100 mg/m2 (with
ketoconazole)
350 mg/m2 (alone)
Q3W
SN-38
APC
AUC500 109% :
AUC500 87% ;
[142]
Lopinavir 400 mg/ritonavir 100 mg
combination drug (Kaletra) bid
8 CYP3A4
UGT1A1
ABCB1
150 mg/m2
D1? 10, Q3W
Irinotecan
SN-38
SN-38G
APC
AUCinf 89% :,
CL 47% ;
AUCinf 204% :
AUCinf 94% :
AUCinf 81% ;
[148]
Cyclosporine 5–10 mg/kg 43 ABCB1
ABCC2
25–75 mg/m2 Q1W Irinotecan
SN-38
CL 39–64% ;
AUC24
23–630% :
[147]
Cyclosporine ?
Phenobarbital 90 mg for 14D
39 ABCB1
ABCC2
UGT1A1
72–144 mg/m2 Q1W Irinotecan
SN-38
SN-38G
AUC24 27% ;,
CL 43% :
AUC24 75% ;
AUC24 50% ;
Celecoxib 400 mg bid 11 50–60 mg/m2
D1? 8, Q3W
Irinotecan
SN-38
CL 18% :
AUC12.5 21.8% ;
[151]a
Methimazole 14 UGT1A 660 mg
Q3W
SN-38
SN-38G
AUC56 14%:
AUC56 67% :
[150]
Herbal and dietary supplements, and lifestyle
Cigarette smoking 190 CYP3A
UGT1A1
350 mg/m2 or
600 mg fixed dose
Q3W
Irinotecan
SN-38
AUC100 15% ;,
CL 18% :
AUC100 38% ;
[162]
St. John’s wort 300 mg tid 5 CYP3A4 350 mg/m2
Q3W
SN-38 AUC24 42% ; [158]
All PK alterations mentioned are significant at p\0.05
N sample size, D day, od once daily, bid twice daily, tid three times daily, AUC area under the curve, inf infinity, CL clearance, Q1W every week,
Q2W every 2 weeks, Q3W every 3 weeks, PK pharmacokinetics, CYP cytochrome P450, Cmax maximum concentration, 5-FU 5-fluorouracil
aFor thalidomide and celecoxib, conflicting data have been published between pharmacokinetic drug interactions with irinotecan. Studies that did
not show a significant drug–drug interaction [131, 132, 152, 153] are illustrated in more detail in the text
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must be avoided (if possible), or dosing must be guided on
irinotecan pharmacokinetics to ensure a sufficient expo-
sure. In addition, Innocenti et al. found a decreased expo-
sure to SN-38 when irinotecan was combined with
cyclosporine and the AED phenobarbital (Table 1) [147].
In addition, an important DDI between irinotecan and
the combination treatment with ritonavir and lopinavir,
caused by CYP3A4, UGT1A1, and ABC transporter inhi-
bition resulted in a more than twofold increase in SN-38
AUC and a 36% decrease in the SN-38G/SN-38 AUC ratio
(Table 1) [148]. A similar effect could be expected of
atazanavir, which is also a strong inhibitor of CYP3A4 and
UGT1A1 [149]. In contrast, by UGT1A induction by
methimazole, an increase in SN-38 and SN-38G concen-
trations, as well as an almost 50% increased ratio of SN-
38G/SN-38, was found by within-patient comparison
(Table 1) [150].
With regard to frequently used drugs such as NSAIDs
and proton pump inhibitors, only a possible DDI with
celecoxib and omeprazole has been evaluated to date. One
of three studies investigating the coadministration of
irinotecan and celecoxib described an increased clearance
of irinotecan and a decreased AUC of SN-38, although the
mechanism is not clear (Table 1) [151–153]. Although
omeprazole influences UGT, CYP3A, ABCB1, and
ABCG2, a clinically relevant pharmacokinetic interaction
with irinotecan was ruled out in a small crossover study
[154].
2.5.3 DDIs with Herbal and Dietary Supplements,
and Lifestyle
In general, herbal and dietary supplements are frequently
used by cancer patients [155, 156]. Unfortunately, the
potential for herb–drug interactions in oncology is not
frequently investigated in clinical studies [157]. To date,
the effects of St. John’s wort (SJW), milk thistle, cigarette
smoking, and cannabis tea on irinotecan pharmacokinetics
have been investigated. Concomitant use of SJW resulted
in a 42% reduction of SN-38 AUC, primarily caused by
CYP3A4 induction (Table 1) [158]. Flavonoids are com-
ponents of many herbs, such as milk thistle (Silybum
marianum), and are able to inhibit CYP3A4, UGT1A1 and
ABC transporters [159–161], but an interaction has not yet
been demonstrated in clinical trials [161].
Cigarette smoking resulted in a decrease in irinotecan
and SN-38 exposure, possibly caused by CYP3A induction
(Table 1) [162]. In addition, (medicinal) cannabis can
induce CYP3A4 and inhibit ABCB1, and its use is
becoming more popular in cancer patients. Although no
interaction was demonstrated between irinotecan and
medicinal cannabis tea [163], other cannabis formulations
contain different concentrations of the enzyme-modulating
compounds (e.g. cannabidiol and delta-9-tetrahydro-
cannabinol [THC]). Therefore, it remains unclear if
cannabinoid oils, the most popular formulation nowadays,
are safe in combination with irinotecan.
3 Pharmacodynamics
3.1 Toxicity
Irinotecan is known for its dose-limiting adverse events,
primarily diarrhea, neutropenia, and asthenia. Of patients
with irinotecan monotherapy, 16–31% experience severe
diarrhea, and a comparable percentage of patients suffer
from severe neutropenia and severe asthenia, classified as
Common Terminology Criteria for Adverse Events
(CTCAE) grade 3 or worse [164–168]. Patients treated
with a 5-fluorouracil, leucovorin and irinotecan (FOLFIRI)
regimen experience severe diarrhea (9–44%) and severe
neutropenia (18–54%) to the same extent [168–173]. In
addition, neutropenia appears to occur more frequently in
females [174]. Although irinotecan dose is lower in this
regimen, 5-fluorouracil could also cause these adverse
events.
Two types of diarrhea caused by irinotecan can be dis-
tinguished: early- and late-onset diarrhea. Early-onset
diarrhea starts during, or immediately after, drug infusion
and is caused by increased cholinergic activity, which
stimulates intestinal contractility and reduces the absorp-
tive capacity of the mucosa [175]. In addition, early-onset
diarrhea is often part of an acute cholinergic syndrome with
diaphoresis and abdominal pain. The overall incidence of
this syndrome is approximately 70% without premedica-
tion, and is reduced to 9% by administration of anti-
cholinergic agents (i.e. atropine or hyoscyamine) before
irinotecan infusion [176, 177]. Late-onset diarrhea occurs
approximately 8–10 days after irinotecan infusion and is
characterized by a more severe course, which is probably
caused by damage of the intestinal mucosa due to increased
oxidative stress by biliary-secreted or intestinally decon-
jugated SN-38 [76, 178–180]. Several guidelines recom-
mend treating late-onset diarrhea with loperamide or,
alternatively, octreotide [181, 182]. Antibiotics have also
been used in clinical practice despite sufficient evidence
supporting this strategy [182]; however, these interventions
are not always sufficient, which could lead to dose reduc-
tions, treatment interruptions and hospitalization.
Conflicting results have been reported regarding the
relationship between irinotecan and SN-38 exposure and
toxicity (Table 2) [60]. An initial study suggested the bil-
iary index (i.e. the ratio of SN-38 to SN-38G AUCs mul-
tiplied by the AUC of irinotecan) as a better predictor for
gastrointestinal toxicity [178]. Studies on this subject have
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been contradictory; a higher biliary index was significantly
correlated with a higher incidence of severe diarrhea in
several studies [76, 178, 183], whereas no significant
association was found in other studies (see Table 2)
[16, 66, 68, 184]. The duration of neutropenia has been
found to be significantly correlated to prolonged systemic
SN-38 exposure [73].
Several interventions to prevent diarrhea have been
investigated, such as reducing the intestinal exposure of
SN-38. First, in a phase I study, SN-38 excretion in the bile
was inhibited by combining irinotecan with cyclosporine
(due to ABCC2 and ABCB1 inhibition). Subsequently,
phenobarbital (as a UGT1A1 inductor) was added, and the
combination of cyclosporine/phenobarbital/irinotecan
resulted in a 75% reduction of SN-38 AUC [147]. How-
ever, when studied in a large, randomized, phase III trial,
the combination of cyclosporine, irinotecan and panitu-
mumab did not significantly reduce the incidence of severe
Table 2 Irinotecan toxicity in relation to pharmacokinetics and biliary index
Study, year N Irinotecan dose Irinotecan SN-38 SN-38G Biliary index
Diarrhea
Ohe et al., 1992 [185] 36 5–40 mg/m2
5D, continuously
Yesa No ND ND
de Forni et al., 1994 [186] 59 50–145 mg/m2 Q1W Yesa Yesa ND ND
Rowinsky et al., 1994 [65] 32 100–345 mg/m2 Q3W No No ND ND
Gupta et al., 1994 [178] 21 100–175 mg/m2 Q1W No No No Yesb
Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesc Yesc ND ND
Catimel et al., 1995 [67] 46 33–115 mg/m2
D1–D3, Q3W
Yesa No ND ND
Gupta et al., 1997 [76] 40 145 mg/m2 Q1W No No No Yesb
Canal et al., 1996 [68] 47 350 mg/m2 Q3W No No No No
Mick et al., 1996 [183] 36 145 mg/m2 Q1W ND ND ND Yesa
Rothenberg et al., 1996 [188] 48 125–150 mg/m2 Q1W No Yesa ND ND
Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No
de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No No ND No
Xie et al., 2002 [16] 109 100–350 mg/m2 Q3W Yes1 No Yesa No
Neutropenia
Ohe et al., 1992 [185] 36 5–40 mg/m2
5D, continuously
No Yesd ND ND
de Forni et al., 1994 [186] 59 50–145 mg/m2 Q1W Yese Yese ND ND
Rowinsky et al., 1994 [65] 32 100–345 mg/m2 Q3W No Yese ND ND
Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesd Yesd ND ND
Catimel et al., 1995 [67] 46 33–115 mg/m2
D1–D3, Q3W
No No ND ND
Canal et al., 1996 [68] 47 350 mg/m2 Q3W Yese Yese No No
Rothenberg et al., 1996 [188] 48 125–150 mg/m2 Q1W No No ND ND
Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No
de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No No ND ND
Mathijssen et al., 2002 [73] 26 350 mg/m2 Q3W ND Yesf ND ND
All assumed relationships mentioned are significant at p\0.05
N sample size, ND not determined, D day, Q1W every week, Q3W every 3 weeks
aDiarrhea frequency, all grades
bDiarrhea gradeC 3
cDiarrheaC 2
dAbsolute decrease in neutrophil count, all grades
ePercentage decrease in neutrophil count, all grades
fEntire time course of absolute neutrophil count decrease
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diarrhea [189]. In another randomized trial, prophylactic
use of racecadotril, an antisecretory drug, also failed to
reduce this adverse event [190]. Alternatively, SN-38 can
be bound to activated charcoal or calcium aluminosilicate
clay in the intestine. Until now, only the activated charcoal
has been found to reduce the incidence of diarrhea
[191, 192]; however, evidence from a phase III study and
additional pharmacokinetic analysis is warranted to
understand the real effect of activated charcoal, which also
exhibits a general antidiarrhoeic effect, and therefore the
use of charcoal is not common practice.
Another attempt to reduce toxicity was by inhibition of
b-glucuronidase production by antibiotics (i.e. strepto-
mycin, penicillin, and neomycin), amopaxine, and herbal
medicines, all without a relevant reduction in diarrhea
incidence [56–58, 193]. However, when combined with
cholestyramine to reduce reabsorption, b-glucuronidase
inhibition by levofloxacin was found to reduce irinotecan-
induced diarrhea [194]. In addition, a randomized double-
blind, placebo-controlled trial showed a 20% reduction in
diarrhea incidence when irinotecan was combined with
probiotics. Unfortunately, this did not result in a significant
difference between groups, probably due to a lack of sta-
tistical power [195]. Lastly, altering the intestinal envi-
ronment by alkalinization or reduction of inflammation (by
the use of budesonide) did also not reduce intestinal toxi-
city [196–201].
Currently, fasting before chemotherapy is investigated
to reduce toxicity, which has been shown to be effective in
mice without affecting the anticancer effects. Systemic and
hepatic exposure to SN-38 was reduced in these mice, but
intratumoral concentrations were unaltered [202, 203]. A
prospective trial is currently ongoing in order to assess the
effects of fasting in irinotecan-treated patients and to elu-
cidate the underlying biological mechanisms (http://www.
trialregister.nl/; trial ID: NTR5731).
3.2 Efficacy
Irinotecan is effective in a wide range of malignancies. In
metastatic colorectal cancer (mCRC), irinotecan has its
most prominent role as monotherapy or within combination
therapy. As first-line mCRC treatment, the FOLFIRI regi-
men proved to be superior to 5-fluorouracil with leucovorin
and to irinotecan monotherapy; a response rate (RR) of
39% and median overall survival (OS) of
14.8–17.4 months has been reported [168, 169]; however,
the addition of oxaliplatin to this regimen (i.e. FOLFOX-
IRI) substantially increased treatment efficacy, as shown by
an RR of 60% and median OS of approximately 23 months
[204, 205]. As second-line treatment after 5-fluorouracil-
containing regimens, irinotecan leads to a significantly
longer OS than 5-fluorouracil with leucovorin or best
supportive care (BSC) [166, 167]. For patients with a
KRAS wild-type tumor, efficacy of palliative treatment
could be increased by combining irinotecan monotherapy,
FOLFIRI, or FOLFOXIRI with monoclonal antibodies
(e.g. bevacizumab, cetuximab, panitumumab, ramu-
cirumab) [165, 170–172, 206, 207]. In the adjuvant setting,
the addition of irinotecan to 5-fluorouracil and leucovorin
did not result in a survival benefit [208, 209]. Patients with
tumors characterized by high microsatellite instability
(MSI) have been suggested to respond better to irinotecan-
based chemotherapy, [210, 211] but a recent meta-analysis
failed to show any predictive value of MSI status in rela-
tion to treatment response [212].
For advanced esophageal or junction tumors, irinotecan
has proven to be effective as monotherapy and when
combined with cisplatin, mitomycin, capecitabine and
oxaliplatin, 5-fluorouracil and leucovorin and docetaxel
[213–219]; however, of these regimens, only irinotecan
combined with 5-fluorouracil was evaluated in a phase III
trial in which this combination was inferior to cisplatin/5-
fluorouracil [220]. In advanced human epidermal growth
factor receptor 2 (HER2)-negative gastric cancer, the
addition of irinotecan to different combination therapies
gave an OS benefit in a pooled analysis of ten studies—
median OS was 11.3 months and RR was approximately
38% [221].
Irinotecan is also used in the treatment of small cell lung
cancer (SCLC) and non-SCLC (NSCLC). For advanced
NSCLC, irinotecan combined with taxanes, platinum,
ifosfamide, or gemcitabine demonstrated efficacy as first-
line treatment in several trials [222]. For advanced SCLC,
irinotecan combined with cisplatin or carboplatin had
similar RR and median OS as platinum compounds with
etoposide (RR 39–84% and median OS 9–13 months) and
is therefore used as first-line treatment in Japan, whereas
the etoposide-containing regimen is preferred elsewhere
[223]. Furthermore, irinotecan has demonstrated anticancer
activity in phase II trials in a wide range of other solid
tumors (i.e. mesothelioma, glioblastoma, gynecological
cancers, and head and neck cancer), although no phase III
data are available [224–231].
Finally, in pancreatic cancer, the combination of 5-flu-
orouracil, leucovorin, irinotecan and oxaliplatin (FOL-
FIRINOX) is used for both first-line adjuvant and palliative
treatment in which it was shown to be superior to gemc-
itabine monotherapy (median OS 11.1 months, RR 31.6%)
[232]. Liposomal irinotecan has recently been approved as
second-line treatment for metastatic pancreatic cancer for
patients with progression on gemcitabine-based therapies
[87]. Efficacy of this liposomal formulation needs to be
explored further in other tumor types.
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4 Pharmacogenetics
Expression and functionality of enzymes and drug trans-
porters involved in the metabolism and elimination of
irinotecan can be affected by genetic polymorphisms that
could influence both irinotecan pharmacokinetics and
pharmacodynamics. This section provides an overview of
clinical correlations between polymorphisms and irinote-
can pharmacokinetics and pharmacodynamics.
4.1 Associations between UGT1A1 Polymorphisms
and Irinotecan Pharmacodynamics
With more than 100 reported genetic variants [233],
UGT1A1 is a highly polymorphic enzyme. The most fre-
quently studied UGT1A1 polymorphisms in relation to
irinotecan pharmacokinetics and pharmacodynamics are
UGT1A1*6 and UGT1A1*28. The majority of the genetic
association studies have focused on neutropenia and diar-
rhea as clinical endpoints [169].
Wild-type UGT1A1 is characterized by six thymine
adenine (TA) repeats in the promotor region, whereas
UGT1A1*28 (rs8175347) carriers have an extra TA repeat
that impairs UGT1A1 transcription and thereby reduces
expression by approximately 70% [234]. The incidence of
this genetic variant is relatively high among Caucasians
(minor allele frequency [MAF] 26–39%) and Africans/
African Americans (MAF 30–56%) [235, 236]. Among the
Asian population, UGT1A1*28 is far less common, as
indicated by an MAF of 9–20% [235, 236]. With a reported
MAF of up to 47%, another polymorphism—UGT1A1*6
(rs4148323, 211G[A)—is more common in Asian popu-
lations and may therefore be a better predictor for
irinotecan-related toxicities in that area of the world [237].
UGT1A1*6 also results in an approximately 70% reduction
of UGT1A1 activity in individuals carrying the
UGT1A1*6/*6 genotype [238].
Both UGT1A1*6 and *28 polymorphisms result in an
increased systemic exposure to irinotecan and SN-38 in
patients homozygous for these variants, thereby increasing
the risk of irinotecan-associated adverse events [239, 240].
This is also accompanied by increased financial costs of
toxicity management [241]. Due to the high number of
genetic association studies on the clinical effects of
UGT1A1*6 and *28 on irinotecan pharmacokinetics/phar-
macodynamics and large differences between studies in
terms of tumor type, dosing regimen, and genetic models,
this review will mainly focus on meta-analyses for
UGT1A1*28 and *6 to extract the most relevant informa-
tion with the highest level of evidence (Table 3).
Initially, significant associations between UGT1A1*28
and hematologic toxicities were only reported for
irinotecan doses higher than 180 mg/m2 [242]. However,
more recent meta-analyses did not show a dose-dependent
effect of UGT1A1*28. In addition, *28 carriers receiving
lower irinotecan doses were at risk of neutropenia
[243, 244]. These meta-analyses were carried out in a
predominantly Caucasian population, thus regardless of
scheduled starting dose, genotyping for UGT1A1*28 and
dose reductions in all Caucasian patients homozygous for
UGT1A1*28 may be considered to reduce the risk of severe
neutropenia.
Presumably due to the lower incidence of UGT1A1*28
in the Asian population, the effects of UGT1A1*28 on
toxicity endpoints are less straightforward in this popula-
tion. Several meta-analyses in Asian patients with different
tumor types and treatment schedules did not show any
significant association between UGT1A1*28 and irinote-
can-induced neutropenia [245, 246]. In contrast,
UGT1A1*6 seems to be a more accurate predictor of
irinotecan-induced toxicity; Asian patients with gastroin-
testinal tumors or NSCLC were more likely to suffer from
neutropenia if they were carrying at least one UGT1A1*6
allele (Table 3) [245, 247]. This association does not seem
to be dose-dependent [248].
Both Caucasian and Asian patients homozygous or
heterozygous for UGT1A1*28 have a greater risk of suf-
fering from severe diarrhea compared with wild-type
patients after receiving irinotecan doses [125 mg/m2
[249]. In another meta-analysis among Caucasian *28/*28
carriers, this dose-dependent effect was also observed
[244]. In Asian patients, UGT1A1*6 not only correlates
well with the risk for irinotecan-induced neutropenia but is
also significantly associated with severe diarrhea
[245, 248]. Whether this association is dose-dependent is
currently unknown since no dose subgroup analysis has
been carried out [250].
It seems that response or survival endpoints are not
significantly affected by UGT1A1*6 or *28. Both
UGT1A1*6 and UGT1A1*28 genotypes did not have any
significant association with tumor response in Asian
NSCLC or SCLC patients receiving irinotecan as first- or
second-line chemotherapy [245]. Furthermore, the pres-
ence of one or more UGT1A1*28 alleles in Caucasian
patients with colorectal cancer did not significantly affect
overall and progression-free survival (PFS) [251].
Besides UGT1A1*6 and UGT1A1*28, other common
UGT1A1 polymorphisms could theoretically also affect
irinotecan-related toxicity (Table 3). For instance,
UGT1A1*60 (rs4124874; 3279T[G) is in linkage with
UGT1A1*28 and is associated with a decrease in tran-
scriptional activity [238]. This genetic variant is common
among Caucasians (MAF 47%) and African Americans
(MAF 85%) [252]. Two clinical studies did not report any
significant associations between UGT1A1*60 status and
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Table 3 Overview of pharmacogenetic studies on irinotecan toxicity and survival
Polymorphism Ethnicity Endpoint Dose range
(mg/m2)
Main findings No. of
patients
No. of
studies
References
Meta-analyses
UGT1A1*28/*28
(rs8175347) vs.
*1/*28 or *1/*1
Not reported Hematologic
toxicities
80–125 OR 1.80, 95% CI
0.37–8.84, p = 0.41
229 3 [242]
180 OR 3.22, 95% CI
1.52–6.81, p = 0.008
410 4
200–350 OR 27.8, 95% CI 4.0–195,
p = 0.005
184 3
*28/*28 vs. *1/*1 Mainly Caucasian Neutropenia \150 OR 2.43, 95% CI
1.34–4.39, p = 0.003
300 4 [243]
150–250 OR 2.00, 95% CI
1.62–2.47, p < 0.001
1481 9
C 250 OR 7.22, 95% CI
3.10–16.78, p < 0.001
217 3
*28/*28 vs. *1/*28
or *1/*1
Caucasian Neutropenia 80–350 OR 3.44, 95% CI
2.45–4.82, p < 0.00001
2015 14 [244]
*28/*28 vs. *1/*28
or *1/*1
Diarrhea [150 OR 2.04, 95% CI
1.23–3.38, p = 0.006
1317 8
\150 OR 1.41, 95% CI
0.82–2.43, p = 0.21
663 6
*1/*28 or *28/*28
vs. *1/*1
Asian Neutropenia 50–100 OR 1.47, 95% CI
0.90–2.42, p = 0.13
515 8 [245]
*6/*6 (rs4148323)
vs. *1/*6 or *1/
*1
Diarrhea OR 4.90, 95% CI
2.02–11.88, p = 0.0004
225 4
*6/*6 vs. *1/*6 or
*1/*1
Tumor
response
OR 1.51, 95% CI
0.78–2.92, p = 0.22
225 4
*28/*28 or *1/*28
vs. *1/*1
OR 1.03, 95% CI
0.59–1.82, p = 0.91
390 7
*28/*28 vs. Asian Neutropenia 60–200 OR 1.67, 95% CI 0.94–2.97 658 6 [246]
*6/*28 30–350 OR 2.55, 95% CI
1.82–3.58
886 13
*6/*6 or *28/*28
or *6/*28 vs. *1/
*6 or *1/*28 or
*1/*1
Asian Neutropenia 60–350 OR 3.275, 95% CI
2.152–4.983, p = 0.000
923 11 [247]
*1/*6 or *6/*6 vs.
*1/*1
OR 1.542, 95% CI
1.180–2.041, p = 0.001
994 9
*6/*6 vs. *1/*1 Asian Neutropenia 30–375 OR 4.44, 95% CI
2.42–8.14, p < 0.001
833 7 [248]
*28/*28 or *1/*28
vs. *1/*1
Asian Diarrhea [125 OR 3.02, 95% CI
1.42–6.44, p = 0.004
309 4 [249]
*28/*28 or *1/*28
vs. *1/*1
Caucasian OR 1.93, 95% CI
1.38–2.70, p < 0.001
1096 11
*28/*28 vs. *1/*1
*1/*28 vs. *1/*1
Caucasian OS and PFS 60–350 All comparisons not
significant for both OS
and PFS (p[0.05)
1524 (OS)
1494 (PFS)
10 [251]
Clinical studies
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Table 3 continued
Polymorphism Ethnicity Endpoint Dose range
(mg/m2)
Main findings No. of
patients
No. of
studies
References
UGT1A1*60 Asian PK, tumor
response,
grade 4
neutropenia,
grade 3
diarrhea,
delivered
dose
80 p[0.05 for all endpoints 81 1 [253]
UGT1A1*60 Not specified
(probably
Korean)
Neutropenia,
anorexia,
vomiting,
diarrhea,
abdominal
pain
150 p[0.05 for all endpoints 42 1 [254]
UGT1A1*28, *60,
*93
(rs10929302)
Caucasian (50 pts),
Black (10 pts),
Hispanic (4 pts),
Pacific Islander
(1 pt), Asian (1
pt)
Neutropenia 350 UGT1A1 haplotype (*28/
*60/*93) associated with
grade 4 neutropenia,
p < 0.001
66 1 [255]
UGT1A1*28, *93,
ABCB1
(rs1045642)
Not specified,
presumably
Caucasian
(France)
Hematologic
toxicities
180 UGT1A1*28/*28 and *93/
*93: increased risk of
hematologic toxicity
(p = 0.01)
184 1 [258]
UGT1A1*93,
ABCB1
(rs12720066),
ABCC1
(rs6498588,
rs17501331)
Caucasian (67 pts),
African
American (11
pts)
ANC nadir,
SN-38 AUC
300 or 350 Increased SN-38 AUC:
UGT1A1*93, ABCC1
(rs6498588)
Decreased SN-38 AUC:
ABCB1 (rs12720066)
Increased ANC nadir:
ABCB1 (rs12720066)
Decreased ANC nadir:
UGT1A1*93, ABCC1
(rs17501331)
78 1 [256]
UGT1A1*28 and
*93
Caucasian (94 pts),
Asian (2 pts)
Diarrhea 40–80, 180,
350
UGT1A1*28/*28 and *93/
*93 associated with
grade 3/4 diarrhea
(p < 0.05)
96 1 [260]
Neutropenia No significant effect on
neutropenia
UGT1A1:*28,*93
UGT1A6:
rs2070959
UGT1A9: *22
(rs45625337), -
688A/C variant
UGT1A7*3
30UTR:
440C[G variant
Not specified,
presumably
Caucasian
(Canada)
Neutropenia 180 UGT1A1*93 associated
with neutropenia.
Haplotype (UGT1A1*28,
*60, *93, UGT1A7*3,
UGT1A9*1) associated
with grade 3–4
neutropenia: OR 2.43,
95% CI 1.35–4.39,
p = 0.004
Haplotypes ‘II’ and ‘III’
(variants in UGT1A9,
1A7, 1A6, and 30UTR
wild-type) associated
with grade 3–4
neutropenia: OR 2.15
and 5.28, respectively
167 1 [259]
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Table 3 continued
Polymorphism Ethnicity Endpoint Dose range
(mg/m2)
Main findings No. of
patients
No. of
studies
References
Among other
genes:
UGT1A1*28,
*93
Caucasian (450
pts), African
American (36
pts), Hispanic (16
pts), Asian (9
pts), other (9 pts)
(Febrile)
neutropenia,
vomiting
125 or 200 UGT1A1*93 associated
with grade 3 febrile
neutropenia, grade 4
neutropenia (p < 0.001),
and grade 3 vomiting
(p = 0.004)
520 1 [261]
UGT1A1:*6, *28
UGT1A7*3
UGT1A9*1
Asian Adverse
events,
therapeutic
intervention
60, 70, 100
or 180
UGT1A1*6/*28,
UGT1A7*3/*3 or
UGT1A9*1/*1: greater
risk of adverse events
and therapeutic
intervention: OR 11.00,
95% CI 1.633–74.083,
p = 0.014
45 1 [263]
UGT1A1*28,
UGT1A1*60,
UGT1A1*93,
UGT1A7*3, and
UGT1A9*22
Caucasian Hematologic
toxicity,
response rate
180 Haplotype II (all variants
except UGT1A1*22)
associated with
increased response rate:
OR 8.61, 95% CI
1.75–42.38, p = 0.01
250 1 [262]
Among other
genes:
SLCO1B1
(rs4149056)
UGT1A1*6
UGT1A9*22
ABCC2
(rs3740066)
ABCG2
(rs2231137)
Asian Neutropenia 65 or 80 SLCO1B1 and
UGT1A1*6: increased
risk for grade 4
neutropenia
107 1 [264]
Diarrhea UGT1A9*1/*1,
ABCC2(rs3740066),
ABCG2 (rs2231137):
increased risk for grade
3 diarrhea
Among other
genes:
UGT1A1*93,
ABCC1
(rs3765129),
SLCO1B1*1b
(rs2306283)
African American
(11 pts),
Caucasian (67
pts), other (7 pts)
ANC nadir 300, 350 UGT1A1*93, ABCC1
(rs3765129): decreased
ANC nadir
SLCO1B1*1b (rs2306283):
increased ANC nadir
(p < 0.05)
85 1 [174]
Among other
genes: ABCB1
(rs1045642,
rs1128503,
rs2032582),
Caucasian Toxicity 180 ABCB1 (rs1045642)
associated with early
toxicity: OR 3.79 95%
CI 1.09–13.2
140 1 [268]
Response rate ABCB1 haplotype
(rs1045642, rs1128503,
rs2032582): shorter OS,
OR 1.56, 95% CI
1.01–2.45
ABCC2:
rs1885301,
rs2804402,
rs717620,
rs2273697,
rs17216177,
rs3740066
Caucasian Diarrhea 260–875 mg Decreased incidence of
diarrhea for ABCC2*2
haplotype (rs1885301,
rs2804402, rs717620,
rs2273697, rs17216177,
rs3740066) without
UGT1A1*28 allele: OR
0.15, 95% CI 0.04–0.61),
p = 0.005
167 1 [271]
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irinotecan-related toxicities [253, 254], irinotecan phar-
macokinetics, or tumor response [253]. The only significant
association including UGT1A1*60 was found in a haplo-
type analysis in which a haplotype consisting of
UGT1A1*28, *93 and *60 variant alleles was significantly
associated with grade 4 neutropenia [255].
Similar to UGT1A1*60, UGT1A1*93 (rs10929302;
- 3156G[A) is also in linkage disequilibrium with
UGT1A1*28 [252]. UGT1A1*93 results in reduced
UGT1A1 expression and is associated with elevated
bilirubin concentrations in patients homozygous for
UGT1A1*93 [255]. With an MAF of approximately 30%,
this genetic variant is commonly detected in Caucasians
and African Americans [252]. Clinically, UGT1A1*93 is
associated with increased SN-38 AUC [256], lower neu-
trophil count [257], increased incidence of hematologic
toxicities (including neutropenia) [258, 259], diarrhea
[260], and grade 3 vomiting [261]. Moreover, UGT1A1*93
was also part of a haplotype including variant alleles of
UGT1A1*28, *60, *93, and UGT1A7*3, which was asso-
ciated with increased RR [262]. A prospective trial on
genotype-guided irinotecan dosing based on UGT1A1*28
and UGT1A1*93 genotype status is currently ongoing (trial
ID: NTR6612).
4.2 Associations between Other UGT1A
Polymorphisms and Irinotecan
Pharmacodynamics: UGT1A7 and UGT1A9
Compared with patients with UGT1A9*1/*1, individuals
carrying the UGT1A9*22 genotype (T9[T10; MAF 45%)
show higher enzyme expression and higher SN-38 glu-
curonidation and are therefore more at risk for diarrhea
[263, 264]. Other UGT1A9 variants, UGT1A9*3 (98T[C;
MAF 3%) and UGT1A9*5 (766G[A; MAF 1%), are rare
in Caucasians and are therefore not likely to significantly
affect irinotecan pharmacokinetics and pharmacodynamics
in this population [265]. Lower enzyme activity and SN-38
Table 3 continued
Polymorphism Ethnicity Endpoint Dose range
(mg/m2)
Main findings No. of
patients
No. of
studies
References
Among other
genes: ABCC5
(rs10937158,
rs3749438,
rs2292997)
ABCG1 (rs225440)
Caucasian Diarrhea 180 Reduced risk of diarrhea
for ABCC5 haplotype
(rs10937158 and
rs3749438):
OR 0.39, 95% CI
0.23–0.67, p = 0.0006
167 1 [272]
Neutropenia Increased risk of
neutropenia for co-
occurrence of ABCG1
and ABCC5
(rs2292997): OR 5.93
95% CI 2.25–15.59,
p = 0.0002
SLCO1B1*1b Caucasian Neutropenia 300, 350,
380–600
(mg)
SLCO1B1*1b: increased
ANC nadir (p < 0.05)
67 (discovery
cohort), 108
(replication
cohort)
1 [273]
Among other
genes:
SLCO1B1*1b,
SLCO1B1*5
(rs4149056)
Caucasian SN-38 PK,
toxicity, PFS
180 SLCO1B1*1b: increased
PFS (p < 0.05).
SLCO1B1*5: increased
SN-38 plasma
concentration and
increased risk of
neutropenia (combined
with UGT1A1*28)
(p < 0.05)
127 1 [274]
Significant findings are shown in bold
CI confidence interval, ANC absolute neutrophil count, AUC area under the plasma concentration–time curve, OR odds ratio, OS overall survival,
PFS progression-free survival, PK pharmacokinetics, pt(s) patient(s)
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conjugation is observed in UGT1A7*3 [263] and
UGT1A7*4 polymorphisms [266]. In line with these find-
ings, UGT1A7*3/*3 carriers are at greater risk of adverse
events while receiving irinotecan chemotherapy [262, 263].
A haplotype consisting of UGT1A7*3, UGT1A9*1,
UGT1A1*28, UGT1A1*60, and UGT1A1*93 alleles was
associated with severe neutropenia in a cohort of 167
colorectal cancer patients treated with FOLFIRI [259]. In
the same cohort, UGT1A7*3 was also part of two other
haplotypes, including UGT1A9, UGT1A7, and UGT1A6
variants, associated with an increased risk of grade 3–4
neutropenia (Table 3).
4.3 Associations between Drug Transporter
Polymorphisms and Irinotecan
Pharmacokinetics and Pharmacodynamics
Since both irinotecan and SN-38 are substrates of ABC
transporters (Fig. 2), ABC polymorphisms may also affect
irinotecan pharmacokinetics [267], as well as irinotecan-
related toxicities [174]. In a multivariate analysis including
UGT1A1*93, and ABCC1 single nucleotide polymorphisms
(SNPs) rs6498588 and rs17501331, these variants were
associated with increased SN-38 plasma concentrations
and/or decreased absolute neutrophil counts [256]. The
opposite effects were reported for the ABCB1 variant
rs12720066, which was associated with decreased SN-38
exposure and increased neutrophils. Carriers of another
ABCB1 SNP (rs1045642) had an increased risk for early
toxicity and lower treatment response [268]. In patients
with liver metastases treated with hepatic artery infusion of
irinotecan, oxaliplatin and 5-fluorouracil and intravenous
cetuximab, this SNP was also associated with toxicity
(grade 3–4 neutropenia), increased systemic concentrations
of oxaliplatin and cetuximab, and prolonged PFS [269].
Furthermore, carriers of the ABCB1 haplotype (including
rs1045642, rs1128503, rs2032582) responded less fre-
quently and had shorter survival [268]. In addition to
ABCB1 and ABCC1, polymorphisms of ABCC2
(rs3740066) and ABCG2 (rs2231137) were reported to be
independently predictive for toxicity (i.e. grade 3 diarrhea)
[264]. In contrast, the ABCG2 42 1C[A A NP seems to
have a limited impact on irinotecan exposure [270]. Poly-
morphisms in the gene for the hepatic efflux transporter
ABCC2 may have a protective effect on diarrhea, which is
presumably caused by decreased hepatobiliary transport of
irinotecan and therefore reduced irinotecan exposure to the
gut [271]. This protective effect was observed in Caucasian
patients with the ABCC2*2 haplotype (including six
ABCC2 variants without any UGT1A1*28 alleles).
Although their role in irinotecan efflux has not yet been
established, ABCC5 and ABCG1 could also be involved in
this process since several SNPs in these transporters are
correlated with severe diarrhea [272].
OATP1B1, encoded by the SLCO1B1 gene, is involved
in the hepatic uptake of SN-38 (Fig. 2). In Caucasian
patients carrying at least one SLCO1B1*1b variant allele
(rs2306283; MAF 38%), median neutrophil count
increased approximately twofold compared with wild-types
[273], presumably by increased hepatic uptake of SN-38,
thereby reducing SN-38 plasma concentrations (Table 3).
This result confirms an earlier genetic association study on
the effects of drug transporters on irinotecan neutropenia
and pharmacokinetics [174]. In addition, SLCO1B1*1b was
also associated with increased PFS in patients with col-
orectal and pancreatic cancer [274]. Thus, SLCO1B1*1b
could potentially be a protective biomarker for neutropenia
and may improve efficacy. In contrast, SLCO1B1*5
(rs4149056) leads to reduced transporter activity and was
associated with increased SN-38 plasma concentrations and
an increased risk of neutropenia (in combination with
UGT1A1*28 variant alleles) [274].
4.4 Implementation of Genotype-Adjusted
Irinotecan Dosing Guidelines
Both the US FDA and Health Canada/Sante´ Canada
(HCSC) recommend a reduction of the irinotecan starting
dose in patients who are homozygous for UGT1A1*28
[275, 276] without specifying the extent of reduction
(Table 4). In contrast, the Evaluation of Genomic Appli-
cations in Practice and Prevention (EGAPP) Working
Group did not find sufficient evidence that UGT1A1
genotyping should be used [277]. However, subsequent
guidelines underline the importance of UGT1A1 genotyp-
ing, especially for UGT1A1*28 variant alleles in Western
countries. For example, in France and The Netherlands, a
reduction of the starting dose of 25–30% is recommended
in patients homozygous for UGT1A1*28 receiving higher
doses of irinotecan (C 180 mg/m2) [278, 279]. Regarding
liposomal irinotecan, the European Medicines Agency
(EMA) recommends an initial dose reduction from 80 to
60 mg/m2 in patients homozygous for UGT1A1*28 [280].
In line with the significant associations between
UGT1A1*6 genotype and irinotecan-induced toxicities in
Asian populations, the Japanese Pharmaceuticals and
Medical Devices Agency (PMDA) recommends screening
patients for UGT1A1*6 and *28 polymorphisms [281].
Despite the establishment of these guidelines, UGT1A1
genotyping is currently not routinely performed [282],
which could be explained by the fact that prospective
studies evaluating the clinical effects of genotype-directed
dosing are scarce. Most likely, reduction of the irinotecan
dose to prevent toxicity in carriers of UGT1A1*1/*28 and
UGT1A1*28/*28 is indeed useful since the maximum
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tolerated dose of irinotecan was lower in these patients
relative to wild-type patients [283]. Whether a dose
reduction of irinotecan affects tumor response in
UGT1A1*28 carriers is yet unknown. On the other hand,
patients with the UGT1A1*1/*1 or UGT1A1*1/*28 geno-
type may tolerate higher irinotecan doses than the currently
recommended doses and are therefore at risk of suboptimal
treatment. Indeed, a phase I dose-finding study convinc-
ingly showed that, compared with the recommended
irinotecan dose of 180 mg/m2 in the FOLFIRI regimen,
substantial higher doses of irinotecan (up to 420 mg/m2)
were tolerated in patients wild-type or heterozygous for
UGT1A1*28 [284]. More recently, similar findings were
observed in patients receiving FOLFIRI in combination
with bevacizumab [282], implying that the therapeutic
window of irinotecan may be increased for the UGT1A1*1/
*1 and UGT1A1*1/*28 genotypes.
In summary, particularly for Caucasians, UGT1A1*28
seems to be a good predictor for neutropenia (all irinotecan
doses) and diarrhea (doses[ 125 mg/m2). UGT1A1*28 is
also significantly associated with an increased risk for
diarrhea in Asian patients at irinotecan doses[ 125 mg/
m2. However, in Asian populations the UGT1A1*6 variant
is more common and appears to be a more accurate pre-
dictor for neutropenia (all irinotecan doses) and diarrhea. In
addition to UGT1A1*6 and UGT1A1*28, UGT1A1*93 is
also significantly associated with irinotecan-induced toxi-
city. Less extensively studied polymorphisms such as
UGT1A7*3 and UGT1A9*1, and drug transporter poly-
morphisms (ABCB1, ABCC5, ABCC2, ABCG1, SLCO1B1),
may also be useful predictors for toxicity. Interestingly,
CYP3A4*22 has not been studied thus far, while this SNP
has shown relevance for many other CYP3A substrates
[285–287]. In order to determine the true value of geno-
type-driven dosing of irinotecan, the efficacy of this dosing
strategy should be evaluated prospectively. The inclusion
of additional predictive genetic variants (e.g. UGT1A1*6,
*93) in genotype-directed dosing schedules may improve
their predictive value.
5 Conclusions and Future Perspectives
Irinotecan is a crucial anticancer drug in treatment regi-
mens for several solid tumors. Many factors that con-
tributed to the large interindividual pharmacokinetic
variability have been elucidated. In the last decade, much
progress has been made in unraveling the pharmacogenetic
influence on systemic exposure, toxicity, and survival,
however this knowledge has not yet been sufficiently
translated into general clinical practice.
Table 4 Overview of guidelines on pharmacogenetic testing for irinotecan
Organization Country Year
of last
update
Genotype
recommended
for testing
Dose reduction
explicitly
recommended?
Recommendation References
US FDA USA 2014 UGT1A1*28 Yes UGT1A1*28/*28: starting dose
reduction by at least one dose
level
[275]
Health Canada/Sante´ Canada
(HCSC)
Canada 2014 UGT1A1*28 Yes UGT1A1*28/*28: reduced starting
dose
[276]
National Pharmacogenetics
Network (RNPGx) and the
Group of Clinical Onco-
pharmacology (GPCO-
Unicancer)
France 2015 UGT1A1*28 Yes UGT1A1*28/*28 and dose
180–230 mg/m2: 25–30%
reduction of starting dose
UGT1A1*28/*28 and
doseC 240 mg/m2: irinotecan
contraindicated
[278]
Royal Dutch Association for the
Advancement of Pharmacy
(KNMP)
The
Netherlands
2011 UGT1A1*28 Yes UGT1A1*28/*28 and
dose[250 mg/m2:
30% reduction of starting dose
[279]
European Medicines Agency
(EMA)
Europe 2017 UGT1A1*28 Yes UGT1A1*28/*28: reduce starting
dose of liposomal irinotecan from
80 to 60 mg/m2
[280]
Pharmaceuticals and Medical
Devices Agency (PMDA)
Japan 2014 UGT1A1*6
and *28
No Use irinotecan with caution in
patients with the following
genotypes: UGT1A1*6/*6,
UGT1A1*28/*28 and
UGT1A1*6/*28
[281]
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Based on the pharmacokinetic and pharmacogenetic
data discussed in this review, we recommend dosing
adjustments in the following situations:
• Concomitant use of potent CYP3A4 inducers (e.g.
rifampicin, phenytoin, phenobarbital, carbamazepine,
SJW): avoid combination.
• Concomitant use of potent CYP3A4 inhibitors (e.g.
ketoconazole, itraconazole): avoid combination.
• Caucasians: perform genotyping for UGT1A1*28.
Consider at least a 25% reduction of starting dose in
patients homozygous for UGT1A1*28.
• Asians: perform genotyping for UGT1A1*6. Consider
dose reduction of the starting dose in patients homozy-
gous for UGT1A1*6. Exact dosing adjustments are as
yet unknown.
Future research should prospectively investigate the
added value of individualized irinotecan treatment based
on patient characteristics, pharmacogenetics, and comedi-
cation. Furthermore, novel drug formulations such as
liposomal forms of irinotecan could help to pharmacolog-
ically optimize irinotecan treatment.
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